Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein

被引:121
|
作者
Daub, H
Blencke, S
Habenberger, P
Kurtenbach, A
Dennenmoser, J
Wissing, J
Ullrich, A
Cotten, M
机构
[1] Axxima Pharmaceut AG, D-82152 Martinsried, Germany
[2] Max Planck Inst Biochem, Dept Biol Mol, D-82152 Martinsried, Germany
[3] Tech Univ Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany
关键词
D O I
10.1128/JVI.76.16.8124-8137.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Phosphorylation of hepatitis B virus (HBV) core protein has recently been shown to be a prerequisite for pregenomic RNA encapsidation into viral capsids, but the host cell kinases mediating this essential step of the HBV replication cycle have not been identified. We detected two kinases of 95 and 115 kDa in HuH-7 total cell lysates which interacted specifically with the HBV core protein and phosphorylated its arginine-rich C-terminal domain. The 95-kDa kinase was purified and characterized as SR protein-specific kinase I (SRPK1) by mass spectrometry. Based on this finding, the 115-kDa kinase could be identified as the related kinase SRPK2 by immunoblot analysis. In vitro, both SRPKs phosphorylated HBV core protein on the same serine residues which are found to be phosphorylated in vivo. Moreover, the major cellular HBV core kinase activity detected in the total cell lysate showed biochemical properties identical to those of SRPK1 and SRPK2, as examined by measuring binding to a panel of chromatography media. We also clearly demonstrate that neither the cyclin-dependent kinases Cdc2 and Cdk2 nor protein kinase C, previously implicated in HBV core protein phosphorylation, can account for the HBV core protein kinase activity. We conclude that both SRPK1 and SRPK2 are most likely the cellular protein kinases mediating HBV core protein phosphorylation during viral infection and therefore represent important host cell targets for therapeutic intervention in HBV infection.
引用
收藏
页码:8124 / 8137
页数:14
相关论文
共 50 条
  • [41] Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
    A Mavrou
    K Brakspear
    M Hamdollah-Zadeh
    G Damodaran
    R Babaei-Jadidi
    J Oxley
    D A Gillatt
    M R Ladomery
    S J Harper
    D O Bates
    S Oltean
    Oncogene, 2015, 34 : 4311 - 4319
  • [42] Identification of a dual inhibitor of SRPK1 and CK2 that attenuates pathological angiogenesis of macular degeneration in mice
    Morooka, Satoshi
    Kii, Isao
    Okuno, Yukiko
    Ito, Nobutoshi
    Hagiwara, Masatoshi
    Yoshimura, Nagahisa
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [43] Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice
    Morooka, Satoshi
    Hoshina, Mitsuteru
    Kii, Isao
    Okabe, Takayoshi
    Kojima, Hirotatsu
    Inoue, Naoko
    Okuno, Yukiko
    Denawa, Masatsugu
    Yoshida, Suguru
    Fukuhara, Junichi
    Ninomiya, Kensuke
    Ikura, Teikichi
    Furuya, Toshio
    Nagano, Tetsuo
    Noda, Kousuke
    Ishida, Susumu
    Hosoya, Takamitsu
    Ito, Nobutoshi
    Yoshimura, Nagahisa
    Hagiwara, Masatoshi
    MOLECULAR PHARMACOLOGY, 2015, 88 (02) : 316 - 325
  • [44] Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1
    Schenk, PW
    Stoop, H
    Bokemeyer, C
    Mayer, F
    Stoter, G
    Oosterhuis, JW
    Wiemer, E
    Looijenga, LHJ
    Nooter, K
    NEOPLASIA, 2004, 6 (04): : 297 - 301
  • [45] Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
    Mavrou, A.
    Brakspear, K.
    Hamdollah-Zadeh, M.
    Damodaran, G.
    Babaei-Jadidi, R.
    Oxley, J.
    Gillatt, D. A.
    Ladomery, M. R.
    Harper, S. J.
    Bates, D. O.
    Oltean, S.
    ONCOGENE, 2015, 34 (33) : 4311 - 4319
  • [46] Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis
    Supradit, Kittiya
    Boonsri, Boonyakorn
    Duangdara, Jinchutha
    Thitiphatphuvanon, Thanvarin
    Suriyonplengsaeng, Chinnawut
    Kangsamaksin, Thaned
    Janvilisri, Tavan
    Tohtong, Rutaiwan
    Yacqub-Usman, Kiren
    Grabowska, Anna M.
    Bates, David O.
    Wongprasert, Kanokpan
    TOXICOLOGY IN VITRO, 2022, 82
  • [47] Regulating SR Protein Phosphorylation through Regions Outside the Kinase Domain of SRPK1 (vol 410, pg 131, 2011)
    Plocinik, Ryan M.
    Li, Sheng
    Liu, Tong
    Hailey, Kendra L.
    Whitesides, Jennifer
    Ma, Chen-Ting
    Fu, Xiang-Dong
    Ghosh, Gourisankar
    Woods, Virgil L., Jr.
    Jennings, Patricia A.
    Adams, Joseph A.
    JOURNAL OF MOLECULAR BIOLOGY, 2012, 415 (02) : 454 - 454
  • [48] Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein
    Schüttler, CG
    Fiedler, N
    Schmidt, K
    Repp, R
    Gerlich, WH
    Schaefer, S
    JOURNAL OF HEPATOLOGY, 2002, 37 (06) : 855 - 862
  • [49] Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion
    Bullock, Nicholas
    Potts, Jonathan
    Simpkin, Andrew J.
    Koupparis, Anthony
    Harper, Steve J.
    Oxley, Jon
    Oltean, Sebastian
    JOURNAL OF CLINICAL PATHOLOGY, 2016, 69 (02) : 171 - 175
  • [50] Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis
    Mole, Sarah
    Faizo, Arwa Ali A.
    Hernandez-Lopez, Hegel
    Griffiths, Megan
    Stevenson, Andrew
    Roberts, Sally
    Graham, Sheila, V
    JOURNAL OF GENERAL VIROLOGY, 2020, 101 (05): : 523 - 532